Cargando…

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Noroviruses (NoV) are the leading cause of epidemic acute gastroenteritis in humans worldwide and a safe and effective vaccine is needed. Here, a phase I, double-blind, placebo-controlled clinical trial was performed in 60 healthy adults, 18 to 40 years old. Safety (primary objective) and immunogeni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leroux-Roels, Isabel, Maes, Cathy, Joye, Jasper, Jacobs, Bart, Jarczowski, Franziska, Diessner, André, Janssens, Yorick, Waerlop, Gwenn, Tamminen, Kirsi, Heinimäki, Suvi, Blazevic, Vesna, Leroux-Roels, Geert, Klimyuk, Victor, Adachi, Hiroshi, Hiruta, Kazuyuki, Thieme, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585308/ https://www.ncbi.nlm.nih.gov/pubmed/36275772 http://dx.doi.org/10.3389/fimmu.2022.1021500

Ejemplares similares

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
por: Waerlop, Gwenn, et al.
Publicado: (2023)

The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
por: Janssens, Yorick, et al.
Publicado: (2022)

Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in Nicotiana benthamiana
por: Malm, Maria, et al.
Publicado: (2019)

Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo
por: Tamminen, Kirsi, et al.
Publicado: (2020)

Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform
por: Gröhn, Stina, et al.
Publicado: (2020)

Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses
por: Tamminen, Kirsi, et al.
Publicado: (2021)

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2023)

Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only
por: Heinimäki, Suvi, et al.
Publicado: (2020)

Trivalent Combination Vaccine Induces Broad Heterologous Immune Responses to Norovirus and Rotavirus in Mice
por: Tamminen, Kirsi, et al.
Publicado: (2013)

Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles
por: Malm, Maria, et al.
Publicado: (2016)

Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice
por: Heinimäki, Suvi, et al.
Publicado: (2018)

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Norovirus-Specific Memory T Cell Responses in Adult Human Donors
por: Malm, Maria, et al.
Publicado: (2016)

Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant
por: Tamminen, Kirsi, et al.
Publicado: (2019)

Modular vaccine platform based on the norovirus-like particle
por: Lampinen, Vili, et al.
Publicado: (2021)

Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4(+) T cell immunity within the FLUCOP consortium
por: Begue, Sarah, et al.
Publicado: (2022)

Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co‐delivered with norovirus VLPs
por: Malm, M., et al.
Publicado: (2017)

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2008)

Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group
por: Vandoorn, Elien, et al.
Publicado: (2020)

Human Immunity and Susceptibility to Influenza A(H3) Viruses of Avian, Equine, and Swine Origin
por: Vandoorn, Elien, et al.
Publicado: (2023)

HCV Animal Models: A Journey of More than 30 Years
por: Meuleman, Philip, et al.
Publicado: (2009)

Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium
por: Waerlop, Gwenn, et al.
Publicado: (2022)

Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults
por: Tamminen, Kirsi, et al.
Publicado: (2021)

Testing a compact mobile air purification unit, does it do the job
por: De Waegemaeker, P, et al.
Publicado: (2015)

H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
por: Moris, Philippe, et al.
Publicado: (2010)

Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography
por: Huhti, L., et al.
Publicado: (2012)

Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine
por: Blazevic, Vesna, et al.
Publicado: (2015)

Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus than Sequential Immunization
por: Malm, Maria, et al.
Publicado: (2019)

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults
por: Leroux-Roels, Isabel, et al.
Publicado: (2020)

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial
por: Leroux-Roels, Geert, et al.
Publicado: (2018)

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
por: Aldrich, Cassandra, et al.
Publicado: (2021)

Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo
por: Lappalainen, Suvi, et al.
Publicado: (2014)

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults
por: Lazarus, Rajeka, et al.
Publicado: (2016)

Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: A double-blind randomized trial
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus
por: Schwendinger, Michael, et al.
Publicado: (2020)

LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)
por: Vesikari, Timo, et al.
Publicado: (2019)

Identification of a First Human Norovirus CD8(+) T Cell Epitope Restricted to HLA-A(*)0201 Allele
por: Malm, Maria, et al.
Publicado: (2018)

Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers
por: Poovorawan, Yong, et al.
Publicado: (2012)

Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine
por: Van Damme, Pierre, et al.
Publicado: (2017)

Development of T cell immunity to norovirus and rotavirus in children under five years of age
por: Malm, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tgt05e1csdah1u5tv986tfgrbq